Somaxon Pharmaceuticals ( SOMX ) says it's entered into a settlement agreement with Actavis Elizabeth LLC and Actavis to resolve four patent litigation suits
Somaxon Pharmaceuticals ( SOMX ) says that its licensee Paladin Labs has received approval from Health Canada for its New Drug Submission for its insomnia treatment Silenor. The drug's launch is expected to around mid-2013. Shares +1% AH. Post your comment!
Midday top 10 gainers: BGMD +146% . SOMX +75% . ACUR +56% . TNS +43% . ULBI +18% . MEAD +16% . ESYS +15% . SZYM +14% . GTXI +13% . CLWR +12% . Midday
Premarket gainers: SOMX +101% . TNS +45% . VE +6% . CLDX +5% . URBN +5% . Losers: ESIO -19% . Post your comment!
Midday top 10 gainers: CBAK +80% . ENMD +23% . ANAD +19% . SSE +17% . HOGS +16% . SBLK +15% . CLSN +14% . SOMX +15% . GALT +14% . ACRX +12% . Midday top 10 Losers: SAB -14% . MMR -13% . CNIT -12% . CCCL -14% . BZ -9
By BuySellShort : Somaxon Pharmaceuticals ( SOMX ) has had a tough time of it over the last yea r, f alling from a pre-split adjusted basis of $6 per share to the most recent
Somaxon Pharmaceuticals , Inc. ( SOMX ) Q3 2012 Earnings Conference ..... standing by. Welcome to the Somaxon Pharmaceuticals ' Third Quarter 2012 Conference ..... joining us today to discuss Somaxon Pharmaceuticals ' third quarter 2012 financial
clinical data releases, competitive drugs or treatments, or even the launch of new drugs such as Somaxon Pharmaceutical's ( SOMX ) Silenor or Avanir Pharmaceutical's ( AVNR ) Nuedexta that don't sell particularly well or underperform expectations. Not
By Rx Stocks : There are three selective benzodiazepine-like drugs on the market for insomnia. The first on the market, Zolpidem ( Ambien and Ambien CR ) was marketed by Sanofi-Aventix ( SNY ). Zaleplon ( Sonata ) is made by King Pharmaceuticals and Eszopiclone ( Lunesta ) is made by Sunovion. The
Somaxon Pharmaceuticals , Inc. ( SOMX ) Q2 2012 Earnings Call ..... Operator Welcome to the Somaxon Pharmaceuticals ' second quarter 2012 conference ..... joining us today to discuss Somaxon Pharmaceuticals ' second quarter 2012 financial